![](/img/cover-not-exists.png)
377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)
William G. Paterson, Jonathon Springer, Michael O'Mahony, Richard P. Reynolds, Subhas C. Ganguli, Brian Feagan, Suhail Nurbhai, Steven B. LandauVolume:
134
Year:
2008
Language:
english
DOI:
10.1016/s0016-5085(08)60240-1
File:
PDF, 95 KB
english, 2008